What's the difference between MK-4 and MK-7? Which one should I choose?

MK-4 is metabolized quickly, concentrating its activity in the liver, with a relatively short half-life. MK-7, on the other hand, remains active in the bloodstream for over 72 hours, allowing it to reach extrahepatic tissues like blood vessels and bones more effectively. This is why most vascular clinical trials have used MK-7. Dietary MK-7 comes primarily from fermented soy foods like natto, while MK-4 is found in small amounts in cheese, egg yolks, and poultry.

Do these findings apply to premenopausal women or men?

This study was specifically designed for postmenopausal women with low vitamin K status, so applying results to other populations requires caution. That said, vitamin K insufficiency is widespread across age groups and sexes, and MGP's protective role in vascular tissue operates independently of gender. If vascular health is a priority, checking whether your diet provides adequate vitamin K is a reasonable starting point.

I'm on warfarin. Is it safe to take K2?

No, not without medical guidance. Vitamin K directly interacts with warfarin and other vitamin K antagonists. Adding a K2 supplement can unpredictably alter anticoagulation effects. If you are taking any anticoagulant medication, speak with your doctor before adding K2 in any form.

Vitamin K2 MK-7 in 165 Postmenopausal Women: New Post-Hoc Vascular Findings

Vascular aging doesn’t follow the same calendar as your birthday. After menopause, as estrogen declines, arterial walls begin losing elasticity. The heart has to work harder to push blood through stiffer vessels. Blood pressure climbs. Vascular compliance drops. It is a quiet, gradual shift, and for a long time there were few reliable tools to slow it.

A post-hoc analysis published in Nutrients in February 2025 added a specific piece to this picture: 165 vitamin K-insufficient women aged 40 to 70, one year of MK-7, and some notable changes in vascular measures.

The Calcium Paradox

For anyone paying attention to bone health, calcium supplementation seems straightforward. But researchers have long observed a puzzling pattern: calcium intake doesn’t reliably translate to stronger bones, and in some cases, calcium appears to accumulate in arterial walls instead.

The term that circulates in the research community is the “calcium paradox.” Calcium itself isn’t the problem. The problem is when the signaling that directs calcium to the right places stops working properly. Matrix Gla Protein, or MGP, is one of the key regulators in this system.

MGP: The Protein That Keeps Calcium in Its Place

MGP is the most potent known inhibitor of vascular calcification. It works by binding to calcium in arterial walls and preventing it from crystallizing there. But MGP only becomes active when carboxylated, a process that requires vitamin K.

When vitamin K is insufficient, MGP circulates in an inactive form called dp-ucMGP (dephosphorylated-uncarboxylated MGP). Elevated dp-ucMGP is now used as a biomarker for poor vitamin K status and heightened vascular calcification risk. In this study, reducing dp-ucMGP was a central outcome measure.

MK-4 vs. MK-7: The Same Name, Different Behavior

Vitamin K2 exists in several forms called menaquinones. The two most common in food and supplements are MK-4 and MK-7.

MK-4 has a short half-life, is metabolized rapidly, and its action is concentrated in the liver. It appears in small amounts in cheese, egg yolks, and poultry.

MK-7 has a half-life exceeding 72 hours. A single daily dose maintains stable blood levels throughout the day, and more of it reaches extrahepatic tissues, including vessel walls and bone. This is why virtually all the clinical trials examining vascular outcomes have used MK-7 specifically. The primary dietary source of MK-7 is fermented soy, particularly natto and Korean cheonggukjang.

What the 165-Woman Post-Hoc Found

The Nutrients analysis was a post-hoc examination of a one-year randomized controlled trial in vitamin K-insufficient women aged 40 to 70. Eighty-two women received 180μg/day of MK-7 (MenaQ7®) and 83 received placebo.

Across the full cohort, the MK-7 group showed significantly greater reductions in dp-ucMGP compared to placebo, confirming that vitamin K status genuinely improved with supplementation.

The most clinically interesting signal came from a subgroup of postmenopausal women with elevated baseline arterial stiffness. In this subset, MK-7 supplementation produced significant improvements in both blood pressure and vascular compliance. Women with lower baseline stiffness did not show the same magnitude of change. The implication: MK-7 appears to have the most measurable effect when vascular deterioration is already underway.

This tracks with findings from the three-year University of Maastricht trial (244 healthy postmenopausal women, ages 55 to 65). In that study, the placebo group showed progressive increases in pulse wave velocity (PWV, a standard measure of arterial stiffness), while the MK-7 180μg group held steady, with statistically significant differences emerging by year three. Women with baseline stiffness index above the median of 10.8 showed additional improvements in vascular compliance, distensibility, and elasticity. dp-ucMGP fell by approximately 50% relative to placebo in that trial.

Current clinical guidelines do not position K2 as a treatment to reverse existing vascular calcification. The evidence supports slowing the progression, not reversal.

The Vitamin D + K2 + Magnesium Triad

K2 doesn’t work in isolation. The same activation process that applies to MGP also applies to osteocalcin, a protein that helps direct calcium into bone matrix. Here is where vitamin D becomes relevant. Vitamin D increases calcium absorption in the gut. For that absorbed calcium to reach bone rather than soft tissue, the K2-dependent proteins need to be active.

The concern, raised in several research contexts, is that supplementing vitamin D without adequate K2 may increase calcium absorption without improving its destination. This isn’t established as clinical harm, but it has become a reason to consider D and K2 together.

Magnesium connects in two ways. It is required as a cofactor in the enzymatic activation of vitamin D itself. And separately, magnesium has been associated with reduced arterial calcification in observational data. The three nutrients are increasingly considered in combination.

The AVADEC trial explored a high-dose combination approach. In patients with aortic valve calcification, vitamin K2 720μg plus D3 25μg daily for 24 months reduced dp-ucMGP by over 255 pmol/L versus placebo. Biomarker improvement was substantial. However, this did not translate to a statistically significant reduction in calcification scores on imaging. The data confirm that high-dose K2 can meaningfully activate MGP, while also showing that structural vascular change requires longer observation windows and possibly different patient populations.

Can Diet Realistically Get You There?

At 180μg/day, food becomes a useful lens. Natto contains approximately 800 to 1,000μg of MK-7 per 100g, meaning even a 30g serving (about two tablespoons) approaches the clinical dose. Natto is the most viable dietary route by a significant margin.

Korean cheonggukjang is fermented differently from Japanese natto, and MK-7 content varies considerably between products, making consistent intake harder to quantify.

Other sources fall short of the clinical range. Aged cheeses such as Edam and Gouda contain a mix of MK-4 and some longer-chain MK forms, typically in the 30 to 50μg range. Egg yolks and poultry contribute MK-4 in small quantities. These add to dietary diversity but won’t approach the amounts used in the trials.

For supplementation, look for products that specify MK-7 content in micrograms (μg) on the label. Products labeled simply “vitamin K2” may contain MK-4 only, or lower doses than they appear to suggest.

A Clear Line for Warfarin Users

Vitamin K plays a direct role in the blood coagulation cascade. Warfarin and similar vitamin K antagonists work precisely by blocking this pathway. Adding K2 supplementation can alter anticoagulant effects unpredictably. Anyone currently on warfarin, acenocoumarol, or any anticoagulant should not add K2 without explicit guidance from their prescribing physician.

For everyone else: before adding a standalone K2 supplement, check whether your current multivitamin or combination supplement already contains it. Many do, in varying amounts.

The vascular changes after menopause unfold gradually and without obvious signals. This post-hoc analysis adds evidence that in postmenopausal women with already elevated arterial stiffness, MK-7 at 180μg/day produced measurable improvements over 12 months. If dietary MK-7 is limited, a targeted supplement is a reasonable approach. The condition: verify what you’re already taking before adding more.

Source: Nutrients (MDPI)